Obstetric and neonatal outcomes after preterm premature rupture of membranes among women carrying group B streptococcus

Yael Ganor-Paz, David Kailer, Gil Shechter-Maor, Rivka Regev, Moshe D. Fejgin, Tal Biron-Shental*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective To evaluate whether carriers of group B streptococcus (GBS) have adverse obstetric and neonatal outcomes when preterm premature rupture of membranes (PPROM) occurs. Methods In a retrospective study, data were reviewed for women with a singleton pregnancy and PPROM before 34 weeks who attended the Meir Medical Center, Kfar Saba, Israel, between 2005 and 2012. All women received roxithromycin for 1 week, and ampicillin until GBS culture results were available. Ampicillin was continued to 1 week if the GBS culture was positive. The primary study outcome measure was the latency period (time from rupture of membranes to active/induced labor). Results Among 116 eligible patients, 21 (18.1%) were GBS carriers and 95 (81.9%) noncarriers. The latency period was 11.2 ± 18.1 days for GBS carriers versus 7.5 ± 9.6 days for noncarriers (P = 0.93). However, there was a correlation between the length of ampicillin treatment and the latency period (Spearman correlation coefficient 0.7; P < 0.001). There were no differences in early neonatal outcomes. Conclusion GBS carriers with PPROM did not have adverse outcomes. Longer treatment with ampicillin among GBS carriers prolonged the latency period.

Original languageEnglish
Pages (from-to)13-16
Number of pages4
JournalInternational Journal of Gynecology and Obstetrics
Issue number1
StatePublished - 1 Apr 2015


  • Adverse obstetric outcomes
  • Group B streptococcus
  • Latency period
  • Preterm premature rupture of membranes


Dive into the research topics of 'Obstetric and neonatal outcomes after preterm premature rupture of membranes among women carrying group B streptococcus'. Together they form a unique fingerprint.

Cite this